---
document_datetime: 2026-01-13 10:25:57
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/neparvis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: neparvis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.3875555
conversion_datetime: 2026-01-14 07:24:56.693374
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Neparvis

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber   | Scope                       | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA / | A.ADMINISTRATIVECHANGES-A.7 | 12/01/2026                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000319973                     | Deletion of manufacturing sitesfor an active substance, intermediate or finished product, packaging site,manufacturerresponsiblefor batch release, site where batch control takes place,orsupplierof astartingmaterial, reagent orexcipient(when mentioned in the dossier)*- Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.b The activities for whichthemanufacturer/importeris responsibledonotincludebatchrelease- Accepted                                                      |            |     | PL   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IA / EMA/VR/0000278105 | A.ADMINISTRATIVE CHANGES-A.4 Change in the name and/or address of:a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate usedinthemanufactureof the active substance(where specified in the technical dossier)wherenoPh.Eur.Certificateof Suitabilityispartof theapproveddossier;or amanufacturerofanovelexcipient(where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in thename and/or address of:a manufacturer(includingwhererelevant | 19/06/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

| quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureof the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier)- Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of theactive substance-Accepted B.I.a.3 Change inbatch size(including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to10-foldincreasecomparedtothe originally approved batch size -Accepted B.III.1.a EuropeanPharmacopoeial CertificateofSuitability totherelevantPh. Eur.Monograph-B.III.1.a.2 Updated certificate from an already approved manufacturer-Accepted B.I.a.3 Change in batch size(including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                          | Upto10-foldincreasecomparedtothe originally approved batch size - Accepted                                                                                                                                                                                                                                  |            |     |             |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IB / EMA/VR/0000244218    | This was an application for a variation following a worksharing procedure according toArticle20of CommissionRegulation(EC) No 1234/2008. B.III.1.a EuropeanPharmacopoeial CertificateofSuitability totherelevantPh. Eur.Monograph-B.IlI.1.a.z Othervariation - Accepted                                     | 05/06/2025 | N/A |             |
| Variation type IA_IN / EMA/VR/0000244315 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, LabellingorPackageLeafletintendedto implementtheoutcomeofaPRACsignal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted | 21/02/2025 |     | SmPC and PL |